Subscribe: My Business Wire News
http://home.businesswire.com/portal/site/home/index.jsp?epi-content=GENERIC&epi-process=generic.jsp&beanStrID=bwrss&viewID=headline_list_rss&rss=G1QFDERJXkJeEFpRXEMGSQ5SVFRVE0RWEERZVUUDGkRJXhFYWFxSEw=
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  announces  business wire  business  company  data  new  patients  phase  time  today announced  today  wire 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: My Business Wire News

My Business Wire News



Custom News Interest Profile: Primary



Published: Sun, 4 Dec 2016 22:30:46 UT

Last Build Date: Sun, 4 Dec 2016 22:30:46 UT

Copyright: Copyright 2016, Business Wire.
 



SKY Expands Partnership with Netcracker to Deliver Best-in-Class Customer Experience

Sun, 4 Dec 2016 22:00:00 UT

WALTHAM, Mass.--(BUSINESS WIRE)--#SKYNZ--Netcracker Technology announces SKY has expanded its partnership to optimize customer experience for its growing digital subscriber base.


Media Files:
http://mms.businesswire.com/media/20161204005033/en/510274/21/NTC_Logo_Horiz_CMYK.jpg




Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan

Sun, 4 Dec 2016 22:00:00 UT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva® (obinutuzumab) plus chemotherapy followed by Gazyva alone head-to-head against Rituxan® (rituximab) plus chemotherapy followed by Rituxan alone for people with previously untreated follicular lymphoma. At a pre-planned interim analysis in May 2016, an independent data monitoring committee


Media Files:
http://mms.businesswire.com/media/20161204005042/en/205253/2/GNE_member_Roche_Logo.jpg




bioMérieux: Information Réglementée – déclaration de transactions sur actions propres

Sun, 4 Dec 2016 21:00:00 UT

MARCY L'ETOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM): bioMérieuxsociété anonyme au capital de 12.029.370 eurossiège social : chemin de l'Orme - 69280 Marcy l'Etoile673 620 399 RCS Lyon En application du règlement européen n°596/2014 du 16 avril 2014 sur les abus de marché (« Règlement MAR ») et de son article 5, bioMérieux déclare ci-après les transactions réalisées sur ses actions propres pour la période du 28 novembre au 02 décembre 2016. Présentation agrégée par j


Media Files:
http://mms.businesswire.com/media/20161204005049/fr/504279/21/BIOM_LOGO_TAGLINE_RGB.jpg




How-Dee! Madame Tussauds Nashville Introduces Minnie Pearl as First New Wax Figure

Sun, 4 Dec 2016 19:02:00 UT

NASHVILLE, Tenn.--(BUSINESS WIRE)--Madame Tussauds, the world-renowned wax attraction opening its newest location in Nashville, unveiled a lively Minnie Pearl wax figure during yesterday’s 63rd Annual Nashville Christmas Parade.


Media Files:
http://mms.businesswire.com/media/20161204005064/en/558288/21/NI9A1246.jpg




Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)

Sun, 4 Dec 2016 18:08:00 UT

WILMINGTON, Del.--(BUSINESS WIRE)--Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi (ruxolitinib)


Media Files:
http://mms.businesswire.com/media/20161204005062/en/3588/21/Incyte_2CPos_RGB.jpg




Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Gamma Globin (HBG) Protein Expression for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Sun, 4 Dec 2016 17:30:00 UT

BOSTON--(BUSINESS WIRE)--Acetylon announces oral presentation at ASH on data demonstrating the utility of selective HDAC1,2 inhibition by ACY-957 to induce gamma globin for sickle cell disease and beta-thalassemia.


Media Files:
http://mms.businesswire.com/media/20161204005052/en/350589/21/AcetylonHiRes_PrintLogo.jpg




Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst® and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Sun, 4 Dec 2016 17:01:00 UT

BOSTON--(BUSINESS WIRE)--Acetylon presents early results of Phase1a/1b trial for citarinostat (ACY-241) in combination with Pomalyst and dexamethasone in patients with relapsed or relapsed-and-refractory multiple myeloma.


Media Files:
http://mms.businesswire.com/media/20161204005058/en/350589/21/AcetylonHiRes_PrintLogo.jpg




New Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Sun, 4 Dec 2016 17:00:00 UT

NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion announced that data from an ongoing Phase 1/2 dose-escalation study of ALXN1210 in patients with PNH showed rapid and sustained reductions in LDH in patients treated with once-monthly dosing.


Media Files:
http://mms.businesswire.com/media/20161204005031/en/558163/21/Alexion_Logo.jpg




Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology

Sun, 4 Dec 2016 17:00:00 UT

CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept in patients with lower risk myelodysplastic syndromes (MDS) at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California. Luspatercept is being developed as part of the global collaboration



Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

Sun, 4 Dec 2016 17:00:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company today announced new positive results from its ongoing Phase 2 open-label extension (OLE) study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia A or B without inhibitors. These results were presented today in a poster at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California. New cli


Media Files:
http://mms.businesswire.com/media/20161204005038/en/38833/21/ALNY-Logo_470x314.jpg




Farid Chedid Chairman and CEO of Chedid Re named ‘MEA Industry Achiever of the Year’ at the 2016 MEA Risk & Insurance Excellence Awards

Sun, 4 Dec 2016 13:10:00 UT

BEIRUT, Lebanon--(BUSINESS WIRE)--Farid Chedid Chairman and CEO of Chedid Re named ‘MEA Industry Achiever of the Year’ at the 2016 MEA Risk & Insurance Excellence Awards


Media Files:
http://mms.businesswire.com/media/20161204005046/en/474145/21/Chedid_Re_Logo.jpg




Sunovion to Initiate Recruitment for Aptiom® (eslicarbazepine acetate) Clinical Study with Integrated Digital Health Technology to Aid Seizure Detection

Sun, 4 Dec 2016 13:00:00 UT

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) announced today plans to initiate enrollment for a Phase 4 clinical study (Study 093-701) of Aptiom® (eslicarbazepine acetate). The clinical study will include the use of the Embrace watch by Empatica, an investigational wearable device with unique proprietary technology that will be used to detect and record partial-onset seizures subjectively identified by patients or caregivers. This is the first time that a wearab


Media Files:
http://mms.businesswire.com/media/20161204005040/en/439381/21/Sunovion_logo_without_tagine.jpg




Join IHI for 28th Annual National Forum on Quality Improvement in Health Care

Sun, 4 Dec 2016 11:35:00 UT

--(BUSINESS WIRE)--Press passes are now available for IHI's 28th Annual National Forum on Quality Improvement in Health Care, December 4-7 in Orlando, Florida. Contact joanna@cxocommunication.com for details.


Media Files:
http://mms.businesswire.com/media/20161204005001/en/350604/21/IHI_logo.jpg




Unum Therapeutics to Present on its Antibody-Coupled T-Cell Receptor (ACTR) Platform at the Upcoming 58th American Society of Hematology (ASH) Annual Meeting

Sun, 4 Dec 2016 11:35:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that the Company has been selected for two poster presentations on its Antibody-Coupled T-cell Receptor (ACTR) platform at the 58th ASH Annual Meeting, which is being held in San Diego, California, December 3-6, 2016. In addition, Dr. Michelle Poon of the NUH in Singapore, will be presenting initial results of a


Media Files:
http://mms.businesswire.com/media/20161204005003/en/557857/21/UnumLogo.jpg




Abstract Describing Imara’s Sickle Cell Disease Therapy, IMR-687, Accepted for Oral Presentation at the ASH Annual Meeting

Sun, 4 Dec 2016 11:35:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Imara announced the acceptance of the company’s abstract describing the preclinical efficacy and safety of its lead product candidate, IMR-687, for oral presentation at the ASH meeting on December 4.


Media Files:
http://mms.businesswire.com/media/20161204005002/en/553522/21/Imara_HIres_rgb.jpg




Data at ASH 2016 Show Strong, Lasting Efficacy of Imbruvica®▼ (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukaemia (CLL)

Sun, 4 Dec 2016 09:00:00 UT

BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV today announced the longest follow-up results to date of patients treated with Imbruvica®▼ (ibrutinib) for chronic lymphocytic leukaemia (CLL), showing high and lasting responses through five years.1 These updated Phase 1b/2 data demonstrated an overall response rate (ORR) of 89%,2 including patients with genetic mutations associated with poor outcomes. A complete response (CR) was observed in 29% of patients treated in the first-


Media Files:
http://mms.businesswire.com/media/20161204005044/en/558274/21/Janssen_Cons_RGB.jpg




Sa Sainteté le Pape François prononce une allocution lors du forum mondial Fortune/Time 2016 organisé par Time Inc. au Vatican

Sun, 4 Dec 2016 05:30:00 UT

ROME--(BUSINESS WIRE)--Les 2 et 3 décembre, Time Inc. (NYSE:TIME) a animé le forum mondial Fortune/Time 2016, qui a réuni des PDG de sociétés figurant au Fortune 500, des membres du Time 100 et des chefs de file d'organisations à but non lucratif, universitaires, religieuses et syndicales en vue de répondre au besoin d'un système économique mondial qui à la fois encourage la croissance et répartit ses bénéfices de manière plus large. Les points forts de la conférence de deux jours, qui s'est te


Media Files:
http://mms.businesswire.com/media/20161203005054/en/531786/21/Time_Inc._Logo.jpg




Un discorso di Sua Santità Papa Francesco al Vaticano in occasione del 2016 Fortune/Time Global Forum organizzato da Time Inc.

Sun, 4 Dec 2016 03:36:00 UT

ROMA--(BUSINESS WIRE)--Il 2 e 3 dicembre si è tenuto il 2016 Fortune/Time Global Forum organizzato da Time Inc. (NYSE:TIME) e al quale hanno partecipato vari massimi dirigenti di multinazionali che figurano nell’elenco Fortune 500, membri della lista Time 100 e leader religiosi, sindacali, di istituti di ricerca e universitari, e di organizzazioni non profit, per elaborare delle proposte per un sistema economico che stimoli la crescita e distribuisca su una scala più ampia i benefici che ne der


Media Files:
http://mms.businesswire.com/media/20161203005054/en/531786/21/Time_Inc._Logo.jpg




Seine Heiligkeit Papst Franziskus hält Ansprache auf dem Fortune/Time Global Forum 2016 von Time Inc. im Vatikan

Sun, 4 Dec 2016 03:35:00 UT

ROM--(BUSINESS WIRE)--Am 2. und 3. Dezember rief Time Inc. (NYSE:TIME) im Rahmen seines Fortune/Time Global Forums 2016 Führungskräfte von Fortune-500-Unternehmen aus der ganzen Welt, Mitglieder der Time 100 sowie führende Vertreter von gemeinnützigen, akademischen, religiösen und Gewerkschaftsorganisationen zusammen, um die Notwendigkeit eines globalen Wirtschaftssystems zu erörtern, das nicht nur das Wachstum fördert, sondern auch breiteren Gesellschaftsschichten Vorteile bringt. Die in Rom u


Media Files:
http://mms.businesswire.com/media/20161203005054/en/531786/21/Time_Inc._Logo.jpg




Zijne Heiligheid Paus Franciscus spreekt Time Inc's Fortune 2016/Time Global Forum toe in het Vaticaan

Sun, 4 Dec 2016 03:35:00 UT

ROME--(BUSINESS WIRE)--Op 2 en 3 december bracht Time Inc.’s (NYSE:TIME) 2016 Fortune/Time Global Forum selecte wereldwijde Fortune 500 CEO's, leden van de Time 100 en non-profit, academische, religieuze en vakbondsleiders bijeen om de noodzaak te bespreken van een mondiaal economisch systeem dat zowel de groei stimuleert als de voordelen daarvan breder verspreidt. De tweedaagse conferentie, gehouden in Rome en in het Vaticaan, werd vandaag beëindigd met een speciale pauselijke audiëntie en een


Media Files:
http://mms.businesswire.com/media/20161203005054/en/531786/21/Time_Inc._Logo.jpg




Nordic Nanovector: Single-dose Betalutin® Shows Promising Efficacy, Improved Duration of Response and Favourable Safety in Relapsed NHL Patients

Sun, 4 Dec 2016 02:08:00 UT

OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector ASA (OSE: NANO) presented today the updated results from its ongoing Lymrit 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed non-Hodgkin lymphoma (NHL) at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA). The updated data confirm Betalutin®’s promising efficacy and favourable safety profile as a single agent in 38 relapsed NHL patients, having failed multiple pr



Parrish Medical Center in Florida verpflichtet sich als erstes Krankenhaus auf alle zwölf durchsetzbaren Patientensicherheitslösungen (APSS)

Sun, 4 Dec 2016 00:46:00 UT

IRVINE, Kalifornien (USA)--(BUSINESS WIRE)--Mit Stolz gibt die Patient Safety Movement Foundation (PSMF) bekannt, dass das Parrish Medical Center in Titusville im US-Bundesstaat Florida als erstes Krankenhaus eine formelle Selbstverpflichtung eingegangen ist, die sich auf zwölf der durchsetzbaren Patientensicherheitslösungen Actionable Patient Safety Solutions (APSS) zur Reduzierung vermeidbarer Todesfälle bis 2020 (0X2020) erstreckt. Anfang des Jahres ging das Parrish Medical Center eine Selbs


Media Files:
http://mms.businesswire.com/media/20161201005597/en/557910/21/FishingTrip.jpg




Le Centre médical Parrish en Floride est le premier hôpital à s’engager envers les 12 solutions concrètes pour la sécurité des patients (APSS)

Sun, 4 Dec 2016 00:34:00 UT

IRVINE, Californie--(BUSINESS WIRE)--La  Patient Safety Movement Foundation (PSMF) est très fière d’annoncer que le Centre médical Parrish de Titusville en Floride, est devenu le premier hôpital à prendre des engagements formels en phase avec les 12 solutions concrètes pour la sécurité des patients (Actionable Patient Safety Solutions, APSS) en vue d’éliminer les décès évitables de patients d’ici 2020 (0X2020). Dans le courant de cette année, le Centre médical Parrish a pris neuf engagements gr


Media Files:
http://mms.businesswire.com/media/20161201005597/en/557910/21/FishingTrip.jpg




El Parrish Medical Center de la Florida es el Primer Hospital que se Compromete con las 12 Soluciones Ejecutables para la Seguridad del Paciente (Actionable Patient Safety Solutions, APSS)

Sun, 4 Dec 2016 00:06:00 UT

IRVINE, California--(BUSINESS WIRE)--La  Fundación del Movimiento de Seguridad del Paciente (Patient Safety Movement Foundation, PSMF)  se enorgullece de anunciar que el Parrish Medical Center en Titusville, Florida, se ha convertido en el primer hospital en asumir compromisos formales que se alinean con las 12Soluciones ejecutables para la seguridad del paciente (APPS) para eliminar las muertes prevenibles en pacientes para el 2020 (0X2020). A principios de este año, el Parrish Medical Center


Media Files:
http://mms.businesswire.com/media/20161201005597/en/557910/21/FishingTrip.jpg




Celgene Corporation, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project

Sat, 3 Dec 2016 23:30:00 UT

SAN DIEGO--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG), Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences today announced the creation of the Myeloma Genome Project, a collaborative initiative aimed at compiling the largest dataset of high-quality genomic and clinical data to identify distinct molecular disease segments within multiple myeloma to advance diagnosis, prognosis and treatment of multiple myeloma patients. The initiative seeks to develop clinica



Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting

Sat, 3 Dec 2016 22:45:00 UT

BURLINGTON, Mass.--(BUSINESS WIRE)--$ARQL #ASH2016--ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on its proprietary AKT inhibitor, ARQ 092, in an oral presentation by the University of Illinois College of Medicine at the American Society of Hematology (ASH) Annual Meeting. The presentation highlighted preclinical studies of ARQ 092 in sickle cell disease (SCD). ARQ 092 is an orally available, selective pan-AKT inhibitor. ARQ 092 Oral Presentation Highlights Title: Specific in


Media Files:
http://mms.businesswire.com/media/20161203005009/en/49348/2/2004ArQuleLogo.jpeg




Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma

Sat, 3 Dec 2016 22:00:00 UT

CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL) will be presented in an oral session at the 58th American Society of Hematology (ASH) annual meeting on Saturday, December 3 at 2:15 p.m. PT. Topline data were reported in August 2016


Media Files:
http://mms.businesswire.com/media/20161203005007/en/558143/21/1829444_bizdev_logo-seattle-genetics.jpg




His Holiness Pope Francis Addresses Time Inc.’s 2016 Fortune/Time Global Forum at the Vatican

Sat, 3 Dec 2016 20:11:00 UT

ROME--(BUSINESS WIRE)--On December 2 and 3, Time Inc.’s (NYSE:TIME) 2016 Fortune/Time Global Forum convened select global Fortune 500 CEOs, members of the Time 100 and nonprofit, academic, religious and labor leaders to address the need for a global economic system that both encourages growth and spreads its benefits more broadly. The two-day conference, held in Rome and at the Vatican, culminated today with a Special Papal Audience and an address by His Holiness Pope Francis. His Holiness Pope


Media Files:
http://mms.businesswire.com/media/20161203005054/en/531786/21/Time_Inc._Logo.jpg




Call of Duty World League (CWL), Presented by PlayStation®4, Kicks-off New Season with Invitational Tournament at PlayStation Experience (PSX)

Sat, 3 Dec 2016 20:00:00 UT

ANAHEIM, Calif.--(BUSINESS WIRE)--Call of Duty and PlayStation team up for the 2nd season of Call of Duty World League competition with $4 million in prizing available.


Media Files:
http://mms.businesswire.com/media/20161203005021/en/68172/21/Act_Black_Logo_copy.jpg




Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting

Sat, 3 Dec 2016 20:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today highlighted phase 1b data evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with the frontline standard of care regimen for induction (cytarabine and daunorubicin, also known as 7+3) for younger patients with newly diagnosed acute myeloid leukemia (AML) in an oral presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Di


Media Files:
http://mms.businesswire.com/media/20161203005005/en/395282/21/seagen_logo_3in_4cp_600dpi.jpg




New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Sat, 3 Dec 2016 18:00:00 UT

NEW YORK--(BUSINESS WIRE)--Today, Pfizer Inc. (NYSE:PFE) announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) significantly increased overall survival (OS) when compared to LDAC alone in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who were ineligible for intensive chemotherapy (HR: 0.501, 80% CI: 0.384, 0.654, one-sided log ran


Media Files:
http://mms.businesswire.com/media/20161203005041/en/337677/21/pfizer_rgb_pos.jpg




Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

Sat, 3 Dec 2016 18:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today presented data from a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) combination therapy in frontline diffuse large B-cell lymphoma (DLBCL) at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, expressed on several types of non-H


Media Files:
http://mms.businesswire.com/media/20161203005011/en/395282/21/seagen_logo_3in_4cp_600dpi.jpg




True North Presents Additional Data from an Ongoing Clinical Study Showing Normalization of Hemoglobin Levels with TNT009 in Severely Anemic Cold Agglutinin Disease (CAD) Patients

Sat, 3 Dec 2016 17:30:00 UT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--The interim Phase 1b clinical results presented at ASH further support TNT009 as a promising treatment for CAD, given the normalization of hemoglobin levels seen in severely anemic CAD patients.


Media Files:
http://mms.businesswire.com/media/20161203005003/en/420648/21/TrueNorthLogo_grey.jpg




Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors

Sat, 3 Dec 2016 17:02:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive interim results from Part D of its ongoing Phase 1 study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia with inhibitors. These results were presented today in a poster at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California. New clinical data showed tha


Media Files:
http://mms.businesswire.com/media/20161203005046/en/38833/21/ALNY-Logo_470x314.jpg




Bellicum Announces Updated Clinical Data from BPX-501 Study in Children with Primary Immune Deficiencies and Hemoglobinopathies

Sat, 3 Dec 2016 17:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc.(Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced results from the BP-004 multicenter clinical trial which includes children with Primary Immune Deficiencies (PIDs) and hemoglobinopathies who received an add-back of BPX-501 modified T cells following a haploidentical, T cell-depleted hematopoietic



bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Sat, 3 Dec 2016 17:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced the presentation of new data from the ongoing HGB-205 clinical study evaluating its LentiGlobin product candidate in patients with transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD) at the 58th American Society of Hematology Annual Me


Media Files:
http://mms.businesswire.com/media/20161203005050/en/445600/21/BLUE.jpg




Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

Sat, 3 Dec 2016 17:00:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive initial results from Cohorts 1 and 2 of Part C of its Phase 1 study with givosiran (gi-VOH-si-ran), the International Nonproprietary Name for ALN-AS1, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. These results were presented today in a poster at the 58th Annual Meeti


Media Files:
http://mms.businesswire.com/media/20161203005013/en/38833/21/ALNY-Logo_470x314.jpg




IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of New Oriental Education & Technology Group Inc. and Advises Investors With Losses to Contact the Firm

Sat, 3 Dec 2016 16:52:00 UT

LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against New Oriental Education & Technology Group Inc. (“New Oriental” or the “Company”) (NYSE: EDU) concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com. Reuters published an article December 2, 2016 revealing that


Media Files:
http://mms.businesswire.com/media/20161203005052/en/494879/21/Lundin_Logo_Final.jpg




IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Zimmer Biomet Holdings, Inc. and Encourages Investors With Losses to Contact the Firm

Sat, 3 Dec 2016 16:47:00 UT

IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH). Investors, who purchased or otherwise acquired shares between September 7, 2016 and October 31, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the January 31, 2017 lead plaintiff motion deadline. If you purchased shares of Zimmer during the Class Period, please contact Joon M. Kha


Media Files:
http://mms.businesswire.com/media/20161203005048/en/535336/21/khang_logo.jpg




Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL

Sat, 3 Dec 2016 15:45:00 UT

SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced in a presentation at the 58th American Society of Hematology (ASH) Annual Meeting encouraging early data for JCAR014 in patients with chronic lymphocytic leukemia (CLL) who failed treatment with ibrutinib. Insights from studies of the translational product, JCAR014, are being applied to the development of JCAR01


Media Files:
http://mms.businesswire.com/media/20161203005025/en/484991/21/Juno_RGB.jpg




A Cerevance lançou, com nova tecnologia, a Carteira de Medicamentos e US$ 36 milhões em dinheiro para combater doenças cerebrais

Sat, 3 Dec 2016 14:51:00 UT

OSAKA, Japão e CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502): - Takeda e Lightstone Ventures participam em financiamentos Série A - - Ex-funcionários da Takeda Cambridge no Reino Unido, os programas do CNS mudaram para passar a criar capacidades de descoberta - A Takeda Pharmaceutical Company Limited (TOKYO:4502) e a Lightstone Ventures anunciaram hoje o lançamento da Cerevance, uma empresa de neurociência focada na descoberta e no desenvolvimento


Media Files:
http://mms.businesswire.com/media/20161201006597/en/558105/21/logo_lightstone.jpg




Lanzamiento de Cerevance con Nueva Tecnología, Cartera de Fármacos y 36 Millones de USD en Efectivo para Combatir las Enfermedades Cerebrales

Sat, 3 Dec 2016 13:44:00 UT

OSAKA, Japón y CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO: 4502): - Takeda y Lightstone Ventures participan en ronda de financiación serie A - - Los antiguos empleados de Takeda en Cambridge, R. U. y los programas para tratar el SNC se han trasladado para crear capacidades de descubrimiento llave en mano - Takeda Pharmaceutical Company Limited (TOKYO: 4502) y Lightstone Ventures anunciaron hoy el lanzamiento de Cerevance, una empresa de neurociencia


Media Files:
http://mms.businesswire.com/media/20161201006597/en/558105/21/logo_lightstone.jpg




La société Cerevance a été lancée avec une nouvelle technologie, un nouveau portefeuille de médicaments et 36 millions USD de liquidités pour lutter contre les maladies cérébrales

Sat, 3 Dec 2016 13:39:00 UT

OSAKA, Japon & CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO : 4502) : - Takeda et Lightstone Ventures participent à un financement de Série A - - Anciens employés de Takeda à Cambridge, au Royaume-Uni, les programmes SNC sont allés de l’avant pour créer des capacités de découverte clé en main - Takeda Pharmaceutical Company Limited (TOKYO : 4502) et Lightstone Ventures ont annoncé aujourd'hui le lancement de Cerevance, une société de neuroscience spéci


Media Files:
http://mms.businesswire.com/media/20161201006597/en/558105/21/logo_lightstone.jpg




Panasonic entwickelt das erste*1 IPS-Flüssigkristall-Panel der Branche mit einem Kontrastverhältnis von über 1.000.000:1

Sat, 3 Dec 2016 13:29:00 UT

OSAKA, Japan--(BUSINESS WIRE)--Panasonic Liquid Crystal Display Co. Ltd, eine Tochtergesellschaft der Panasonic Corporation, hat heute die Entwicklung eines neuen Modells ihres IPS-Flüssigkristall-Panels bekannt gegeben. Dieses erreicht ein Kontrastverhältnis[1] von über 1.000.000:1, das damit über dem 600fachen*2 konventioneller Flüssigkristall-Panels liegt. Mit der einzigartigen IPS[2] Flüssigkristalltechnologie von Panasonic, die sich durch große Blickwinkel, hohe Helligkeit und große Zuverl


Media Files:
http://mms.businesswire.com/media/20161203005038/de/558121/21/Panasonic_Graphic_0.jpg




Riassunto: Westinghouse rescinderà come pianificato il contratto di acquisto stipulato con CB&I

Sat, 3 Dec 2016 13:25:00 UT

PITTSBURGH--(BUSINESS WIRE)--Oggi la “corte d’equità” Delaware Court of Chancery ha deliberato in favore di Westinghouse Electric Company e ha rigettato l’istanza di Chicago Bridge & Iron Company N.V. (CB&I) in relazione al processo di riconciliazione successivo alla chiusura. In seguito a questa decisione, le parti ora procederanno in conformità al contratto di acquisto fra esse stabilito e rivolgendosi a una società di revisione indipendente. “Siamo lieti che il giudice abbia determin


Media Files:
http://mms.businesswire.com/media/20161202005756/en/439438/21/westinghouse-negative_logo-blue.jpg




Westinghouse führt CB&I-Kaufvertrag planmäßig weiter

Sat, 3 Dec 2016 13:21:00 UT

PITTSBURGH--(BUSINESS WIRE)--Das Delaware Chancery Court entschied heute zugunsten der Westinghouse Electric Company und wies den Antrag der Chicago Bridge & Iron Company N.V. (CB&I) auf eine Post-Closing-Abgleichung ab. Infolge dieser Entscheidung wird die Kaufvereinbarung der Parteien nun unter Hinzuziehung eines unabhängigen Prüfers planmäßig weitergeführt. „Wir freuen uns, dass das Gericht die Klage für unbegründet erklärt und entschieden hat, dass die Parteien das vereinbarte Anpas


Media Files:
http://mms.businesswire.com/media/20161202005756/en/439438/21/westinghouse-negative_logo-blue.jpg




City of Hope physicians present new research at 2016 American Society of Hematology meeting

Sat, 3 Dec 2016 13:00:00 UT

DUARTE, Calif.--(BUSINESS WIRE)--Clinical trials that lay the groundwork for novel lymphoma, leukemia and multiple myeloma treatments will be among the highlights of the annual meeting of the American Society of Hematology (ASH) in San Diego Dec. 3 to 6. The trials, presented by City of Hope physicians and researchers, could ultimately lead to innovative therapeutic approaches that improve survival and quality of life for patients with those and other diseases. The ASH meeting, which will host



G18+ 承諾共建包容宜居香港

Sat, 3 Dec 2016 12:36:00 UT

香港--(BUSINESS WIRE)--(美國商業資訊)--G18+ 是由一群專業測量師及都市規劃師組成的團隊,一同競逐2016年選舉委員會席位,爭取機會選出香港的下任行政長官。該團隊今天於中環舉行123大會,正式宣布競選計劃。 G18+ 出戰建築、測量、都市規劃及園境界別,團隊陣容包括二十位業界精英,是上述界別中最大的參選隊伍。 大會於交易廣場舉行,一眾建築師、都市規劃師、園境師及測量師均有出席支持。G18+ 召集人劉振江測量師致辭時陳述香港現正面對多項挑戰,並羅列下任特首應具備的條件。 劉先生說:「今天有幸誠蒙大家及另外眾多專業人士支持,G18+將會繼續努力宣揚我們的具體計劃,協助香港在經濟、科技、社會及環境等方面加以改進。G18+ 作為界別中最大的參選隊伍,將致力以專業經驗令香港在工作、消閒及居住等多方面變得更好。」 劉先生在發言中表示,G18+要求行政長官的參選人需要對社會有承擔,著力促進互信及建立共識,令香港更為宜居。」 劉先生續說:「G18+是理性務實的團隊。我們鼓勵行政長官的參選人在作出重大決策前,先聽取意見及尋求持份者支持。我們認為與特首的溝通是雙向的,另外亦要以優


Media Files:
http://mms.businesswire.com/media/20161203005034/en/558275/21/G18%2B_Logo.jpg




G18+ pledges to foster an inclusive and liveable Hong Kong

Sat, 3 Dec 2016 12:35:00 UT

HONG KONG--(BUSINESS WIRE)--G18+, a group of professional surveyors and planners who formed a coalition to contest seats on the Election Committee for Hong Kong’s next chief executive, today launched its campaign at the G18+ 123 Rally in Central, Hong Kong. Competing for the Architectural, Surveying, Planning and Landscape sector, G18+ comprises 20 industry veterans and is the biggest group in the subsector. In a speech at Exchange Square in front of a large crowd of architects, planners, lands


Media Files:
http://mms.businesswire.com/media/20161203005034/en/558275/21/G18%2B_Logo.jpg




Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting

Sat, 3 Dec 2016 12:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) will present new data, including updated longitudinal safety and efficacy findings from phase 3 and extension studies, on the companies’ extended half-life therapies, ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] (marketed as Elocta® in Europe and the Middle East) for hemophilia A and ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] for hemophilia B,


Media Files:
http://mms.businesswire.com/media/20161203005015/en/558257/21/SOBI.jpg




Samenvatting: Panasonic ontwikkelt uniek LC-scherm met IPS voor contrastratio van 1.000.000:1

Sat, 3 Dec 2016 03:44:00 UT

OSAKA, Japan--(BUSINESS WIRE)--Panasonic Liquid Crystal Display Co., Ltd., dochteronderneming van Panasonic Corporation, heeft vandaag bekendgemaakt dat het een nieuw model van zijn panel met vloeibaar kristal (LC) IPS heeft ontwikkeld. Het nieuwe scherm bereikt een contrastratio van 1.000.000:1, oftewel het zeshonderdvoudige van conventionele LC-schermen. Dankzij Panasonics unieke IPS-technologie voor vloeibaar kristal, die zorgt voor een wijde zichthoek, grotere helderheid en betrouwbaarheid,


Media Files:
http://mms.businesswire.com/media/20161202005828/nl/558121/21/Panasonic_Graphic_0.jpg




Panasonic développe le premier*1 panneau à cristaux liquides IPS du secteur ayant un rapport de contraste de plus de 1 000 000:1

Sat, 3 Dec 2016 03:37:00 UT

OSAKA, Japon--(BUSINESS WIRE)--Panasonic Liquid Crystal Display Co., Ltd., une filiale de Panasonic Corporation, a annoncé aujourd'hui le développement d'un nouveau modèle de son panneau à cristaux liquides IPS ayant un rapport de contraste [1] de plus de 1 000 000:1, 600 fois *2 supérieur à celui des panneaux à cristaux liquides traditionnels. Grâce aux technologies de cristaux liquides IPS uniques de Panasonic[2] caractérisées par leurs grands angles de vue, leur luminosité élevée et leur hau


Media Files:
http://mms.businesswire.com/media/20161202005827/fr/558121/21/Panasonic_Graphic_0.jpg




Panasonic desenvolve o primeiro*1 Painel de cristal líquido IPS com relação de contraste superior a 1.000.000:1

Sat, 3 Dec 2016 03:30:00 UT

OSAKA, Japão--(BUSINESS WIRE)--A Panasonic Liquid Crystal Display Co., Ltd., uma subsidiária da Panasonic Corporation, anunciou hoje que desenvolveu um novo modelo de seu painel de cristal líquido IPS que consegue uma relação de contraste[1] superior a 1.000.000:1, o qual é 600 vezes*2 a de painéis convencionais de cristal líquido. Com as exclusivas tecnologias de cristal líquido IPS [2] da Panasonic, que apresentam ângulos de visão amplos, alto brilho e alta confiabilidade, o novo painel IPS a


Media Files:
http://mms.businesswire.com/media/20161202005826/pt/558121/21/Panasonic_Graphic_0.jpg




FERRELLGAS 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Ferrellgas Partners, L.P. – FGP

Sat, 3 Dec 2016 03:07:00 UT

NEW ORLEANS--(BUSINESS WIRE)--$FGP #FGP--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until December 5, 2016 to file lead plaintiff applications in a securities class action lawsuit against Ferrellgas Partners, L.P. (NYSE: FGP). Investor losses must relate to purchases of the Company’s securities between March 11, 2015 and September 28, 2016. This action is pending in


Media Files:
http://mms.businesswire.com/media/20161202005089/en/524707/21/logo.jpg




SUPREME INDUSTRIES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Supreme Industries Inc. – STS

Sat, 3 Dec 2016 03:07:00 UT

NEW ORLEANS--(BUSINESS WIRE)--$STS #STS--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 3, 2017 to file lead plaintiff applications in a securities class action lawsuit against Supreme Industries Inc. (NYSE MKT: STS), if they purchased the Company’s securities between July 22, 2016 and October 21, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court


Media Files:
http://mms.businesswire.com/media/20161202005091/en/524707/21/logo.jpg




CORRECTING and REPLACING Verily Life Sciences Launches Liftware™ Level Device to Help People with Limited Hand and Arm Mobility Eat with Confidence

Sat, 3 Dec 2016 02:07:00 UT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--A multimedia asset accompanying this release has been removed. Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, today announced the commercial launch of its second consumer product, the Liftware™ Level, designed to help individuals with limited hand and arm mobility hold a utensil at the angle needed to easily feed themselves. Liftware Level was designed to help people with limited hand and arm mobility, which may be re


Media Files:
http://mms.businesswire.com/media/20161201005367/en/557869/21/IMG_8849-level_starter_kit.jpg




Westinghouse finalisera comme prévu l'accord d'achat avec CB&I

Sat, 3 Dec 2016 01:44:00 UT

PITTSBURGH--(BUSINESS WIRE)--Aujourd'hui la Delaware Chancery Court s'est prononcée en faveur de la Westinghouse Electric Company et a rejeté la requête de Chicago Bridge & Iron Company N.V. (CB&I) portant sur le processus de réconciliation post clôture. D'après la décision de justice, les parties procéderons en accord avec l'Accord d'achat et solliciterons les services d'un cabinet d'audit indépendant. « Nous sommes satisfaits de la décision du juge, qui a trouvé le dossier infondé et


Media Files:
http://mms.businesswire.com/media/20161202005756/en/439438/21/westinghouse-negative_logo-blue.jpg




Aradigm gibt Topline-Ergebnisse aus zwei Phase-3-Studien bekannt, bei denen Pulmaquin für die chronische Behandlung von Patienten mit nicht zystischer Fibrosis Bronchiectasis mit Lungeninfektionen mit Pseudomonas aeruginosa untersucht wurde

Sat, 3 Dec 2016 00:51:00 UT

HAYWARD, Kalifornien (USA)--(BUSINESS WIRE)--Die Aradigm Corporation (NASDAQ:ARDM) (das „Unternehmen”) hat heute Topline-Ergebnisse seiner beiden Phase-3-Studien (ORBIT-3 und ORBIT-4) bekannt gegeben, bei denen die Sicherheit und Wirksamkeit von Pulmaquin® geprüft wurde, dem proprietären Prüfpräparat des Unternehmens, bei dem täglich einmal Ciprofloxacin inhaliert wird. Untersucht wurden dafür Patienten mit nicht zystischer Fibrosis Bronchiectasis („Non-CF BE”) mit Lungeninfektionen mit Pseudom


Media Files:
http://mms.businesswire.com/media/20161201005450/en/192642/21/aradigm_logo2.jpg




Aradigm annonce les résultats préliminaires de deux études de Phase 3 évaluant le Pulmaquin dans le traitement chronique de patients atteints de bronchectasie sans fibrose cystique et présentant des infections pulmonaires à…

Sat, 3 Dec 2016 00:51:00 UT

HAYWARD, Californie--(BUSINESS WIRE)--Aradigm annonce les résultats préliminaires de deux études de Phase 3 évaluant le Pulmaquin dans le traitement chronique de patients atteints de bronchectasie sans fibrose cystique et présentant des infections pulmonaires à Pseudomonas aeruginosa Aradigm Corporation (NASDAQ : ARDM) (la « Société ») a annoncé aujourd'hui les résultats préliminaires de ses deux essais cliniques de Phase 3 (ORBIT-3 et ORBIT-4) évaluant l'innocuité et l'efficacité du Pulmaquin®


Media Files:
http://mms.businesswire.com/media/20161201005450/en/192642/21/aradigm_logo2.jpg




Kayne Anderson MLP Investment Company Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at November 30, 2016

Sat, 3 Dec 2016 00:48:00 UT

HOUSTON--(BUSINESS WIRE)--Kayne Anderson MLP Investment Company (the “Company”) (NYSE:KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of November 30, 2016. As of November 30, 2016, the Company’s net assets were $2.2 billion, and its net asset value per share was $19.18. As of November 30, 2016, the Company’s asset coverage ratio under the 1940 Act


Media Files:
http://mms.businesswire.com/media/20161202005817/en/184279/2/KYN_logo.jpg




Kayne Anderson Energy Total Return Fund Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at November 30, 2016

Sat, 3 Dec 2016 00:47:00 UT

HOUSTON--(BUSINESS WIRE)--Kayne Anderson Energy Total Return Fund, Inc. (the “Fund”) (NYSE:KYE) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of November 30, 2016. As of November 30, 2016, the Fund’s net assets were $476 million, and its net asset value per share was $13.02. As of November 30, 2016, the Fund’s asset coverage ratio under the 1940 Act w


Media Files:
http://mms.businesswire.com/media/20161202005815/en/184286/2/KYE_logo.jpg




Kayne Anderson Midstream/Energy Fund Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at November 30, 2016

Sat, 3 Dec 2016 00:45:00 UT

HOUSTON--(BUSINESS WIRE)--Kayne Anderson Midstream/Energy Fund, Inc. (the “Fund”) (NYSE: KMF) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of November 30, 2016. As of November 30, 2016, the Fund’s net assets were $384 million and its net asset value per share was $17.41. As of November 30, 2016, the Fund’s asset coverage ratio under the 1940 Act with


Media Files:
http://mms.businesswire.com/media/20161202005813/en/253151/2/KMF_Logo.jpg




Kayne Anderson Energy Development Company Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at November 30, 2016

Sat, 3 Dec 2016 00:44:00 UT

HOUSTON--(BUSINESS WIRE)--Kayne Anderson Energy Development Company (the “Company”) (NYSE: KED) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of November 30, 2016. As of November 30, 2016, the Company’s net assets were $205 million, and its net asset value per share was $19.14. As of November 30, 2016, the Company’s asset coverage ratio under the 1940


Media Files:
http://mms.businesswire.com/media/20161202005811/en/188448/2/KED_logo.jpg




Panasonic Desarrolla la Primera Tecnología de la Industria*1 Panel de cristal líquido IPS con relación de contraste de más de 1 000 000:1

Sat, 3 Dec 2016 00:40:00 UT

OSAKA, Japón--(BUSINESS WIRE)--Panasonic Liquid Crystal Display Co., Ltd., una subsidiaria de Panasonic Corporation, anunció hoy que ha desarrollado un nuevo modelo de su panel de cristal líquido IPS que consigue una relación de contraste[1] de más de 1 000 000:1, que es 600 veces*2 más que la de los paneles de cristal líquido convencionales. Con las tecnologías de cristal líquido IPS[2] exclusivas de Panasonic que ofrecen una amplia variedad de ángulos de visión, alto brillo y gran confiabilid


Media Files:
http://mms.businesswire.com/media/20161202005810/es/558121/21/Panasonic_Graphic_0.jpg




iHeartCommunications, Inc. Announces Amendment to Its Consent Solicitations to Holders of Its Five Series of Priority Guarantee Notes and Senior Notes Due 2021 and Extension of Expiration Time

Sat, 3 Dec 2016 00:34:00 UT

SAN ANTONIO--(BUSINESS WIRE)--iHeartCommunications, Inc. (the “Company”) announced today that it has amended the terms of the six separate consent solicitations (the “Consent Solicitations”) with respect to its five series of priority guarantee notes and senior notes due 2021 (collectively, the “Notes”) that were launched on Monday, November 28, 2016. To eliminate confusion, the terms of the Consent Solicitations have been amended to clarify the language of the proposed amendment to Section 9.0



AMG to Present at the 2016 Goldman Sachs U.S. Financial Services Conference

Sat, 3 Dec 2016 00:06:00 UT

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Sean M. Healey, Chairman and Chief Executive Officer of Affiliated Managers Group, Inc. (NYSE: AMG), and Jay C. Horgen, Chief Financial Officer of AMG, are expected to speak at the 2016 Goldman Sachs U.S. Financial Services Conference in New York on Wednesday, December 7, 2016 at 12:30 p.m. Eastern time. AMG will provide a live audio transmission of the comments through its website at www.amg.com/InvestorRelations. A replay of the webcast will also be ava



Statement of BEST Coalition on Passage of The Exelon Nuclear Bailout Legislation

Fri, 2 Dec 2016 23:37:00 UT

CHICAGO--(BUSINESS WIRE)--The Exelon legislation began as nuclear bailout for plants we don’t need and it ended as a nuclear bailout for plants we don’t need. We urge Governor Rauner to veto this bill.



Kroll Bond Rating Agency Assigns Preliminary Ratings to Elm 2016-1 Trust

Fri, 2 Dec 2016 23:29:00 UT

NEW YORK--(BUSINESS WIRE)--Kroll Bond Rating Agency (KBRA) assigns preliminary ratings to three classes of debt ("the Debt”) issued by Elm 2016-1 Trust. The Initial Loans were originated by MidCap Financial Trust (“the Originator”) and will be serviced by MidCap Financial Services Capital Management, LLC (“MidCap Financial” or “the Servicer”). This transaction is the inaugural securitization for the Originator and Servicer, collectively referred to as “MidCap” or “the Company.” Founded in 2008,


Media Files:
http://mms.businesswire.com/media/20161202005801/en/483434/21/KBRA_Logo_Business_Wire.jpg




Rosen Law Firm Reminds Chesapeake Energy Corporation Investors of Important December 5, 2016 Deadline in Class Action - CHK

Fri, 2 Dec 2016 23:07:00 UT

NEW YORK--(BUSINESS WIRE)--#CHK--Rosen Law Firm Representing Chesapeake Energy Corporation Shareholders in Securities Class Action Seeking to Recover Investor Losses - CHK


Media Files:
http://mms.businesswire.com/media/20161202005798/en/527137/21/Rosen-Law_Logo_-_Golden.jpg




Rosen Law Firm Reminds Supreme Industries, Inc. Investors of Important Deadline in Class Action Filed by Firm - STS

Fri, 2 Dec 2016 23:05:00 UT

NEW YORK--(BUSINESS WIRE)--#STS--Rosen Law Firm Representing Supreme Industries, Inc. Shareholders in Securities Class Action Lawsuit Seeking to Recover Investor Losses - STS


Media Files:
http://mms.businesswire.com/media/20161202005796/en/527137/21/Rosen-Law_Logo_-_Golden.jpg




Celanese Announces Paraformaldehyde Price Increase

Fri, 2 Dec 2016 23:00:00 UT

DALLAS--(BUSINESS WIRE)--$CE #Celanese--Celanese Announces Paraformaldehyde Price Increase


Media Files:
http://mms.businesswire.com/media/20161202005700/en/41562/21/CelLogo_4C.jpg




Centro Médico Parrish da Flórida é o primeiro hospital a se comprometer com todas as 12 soluções acionáveis para a segurança dos pacientes (APSS)

Fri, 2 Dec 2016 22:53:00 UT

IRVINE, Califórnia--(BUSINESS WIRE)--A Patient Safety Movement Foundation (PSMF) tem orgulho de anunciar que o Centro Médico Parrish em Titusville, Flórida, se tornou o primeiro hospital a se comprometer formalmente com todas as 12 soluções acionáveis para a segurança dos pacientes (Actionable Patient Safety Solutions, APSS), que têm como objetivo erradicar mortes evitáveis entre pacientes até 2020 (0x2020). No início deste ano, o Centro Médico Parrish havia assumido nove compromissos, por meio


Media Files:
http://mms.businesswire.com/media/20161201005597/en/557910/21/FishingTrip.jpg




L'Europe doit passer à la vitesse supérieure en matière d'investissement pour concrétiser ses ambitions numériques

Fri, 2 Dec 2016 22:50:00 UT

BRUXELLES--(BUSINESS WIRE)--Lors du Conseil des ministres des télécommunications, la GSMA a demandé aux ministres de s'engager en faveur de l'adoption rapide des réformes du cadre réglementaire des télécommunications, qui stimuleront l'investissement et créeront une « Société gigabit » inclusive dans toute l'Europe. La Commission européenne a présenté des propositions pour un projet de code européen des communications électroniques (CECE) qui servira de base à d'importantes négociations entre l


Media Files:
http://mms.businesswire.com/media/20161202005205/en/505887/21/GSMA_logo.jpg




Fitch: Hot Summer Heated Up 3Q Earnings for U.S. Utilities

Fri, 2 Dec 2016 22:49:00 UT

NEW YORK--(BUSINESS WIRE)--Link to Fitch Ratings' Report: U.S. Utilities: Hot Summer Heats Up Earnings (Third-Quarter 2016 Earnings Wrap-Up) https://www.fitchratings.com/site/re/890842 Hot summer months boosted median third-quarter 2016 (3Q16) earnings for the utility holding companies (UHCs), according to a Fitch Ratings report. Median earnings for 3Q16 grew by 11% year over year (YoY), compared with negative 4% in the 1Q and an 8% increase in the 2Q. Eighty percent of Fitch's sample UHCs affi



Fitch Rates Nassau County (NY) GOs BANs & TAN 'F1'; Affirms GO and IDR

Fri, 2 Dec 2016 22:36:00 UT

NEW YORK--(BUSINESS WIRE)--Fitch Ratings has assigned an 'F1' rating to the following Nassau County, NY general obligation (GO) short-term debt: --Approximately $50,000,000 tax anticipation notes (TANs), 2016 series A; --Approximately $170,000,000 TANs 2016 series B; --Approximately $40,000,000 TANs 2016 series C; and --Approximately $99,000,000 Bond Anticipation Notes (BANs), 2016 Series D (Federally Taxable). In addition, Fitch has affirmed the following ratings: --Approximately $2.1 billion



SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of New Oriental Education & Technology Group Inc. and Advises Investors with Losses to Contact the Firm

Fri, 2 Dec 2016 22:33:00 UT

LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating New Oriental Education & Technology Group Inc. (“New Oriental” or the “Company”) (NYSE: EDU) concerning possible violations of federal securities laws. If you purchased or otherwise acquired New Oriental shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067,


Media Files:
http://mms.businesswire.com/media/20161202005790/en/534554/21/Gold_Logo.jpg




CEMEX to Divest Ready-Mix Concrete Pumping Assets in Mexico

Fri, 2 Dec 2016 22:30:00 UT

MONTERREY, Mexico--(BUSINESS WIRE)--$CEMEX #CEMEX--CEMEX will divest its concrete pumping assets in Mexico to Pumping Team for approximately US$80 million


Media Files:
http://mms.businesswire.com/media/20161202005749/en/530957/21/CX110_languages_English.jpg




BrainCo Inc. to Exhibit at CES 2017

Fri, 2 Dec 2016 22:17:00 UT

BROOKLINE, Mass.--(BUSINESS WIRE)--Press Kit Materials are Available at: http://www.tradeshownews.com/events/ces-2017/brainco-2015/ Company: BrainCo Inc. Booth/Stand: 40715 Event: CES 2017Jan 5 - 8, 2017Las Vegas, NV, US Web: http://brainco.tech Facebook: https://www.facebook.com/braincotech/ Twitter: https://twitter.com/brainco_tech YouTube: https://www.youtube.com/watch?v=C3ICtDH_gtk LinkedIn: https://www.linkedin.com/company/brainco About BrainCo Inc. BrainCo was founded in February 2015, an


Media Files:
http://mms.businesswire.com/media/20161202005788/en/558222/21/BrainCo.Inc_CES.jpg




BlackRock Defined Opportunity Credit Trust Announces Adoption of Plan of Liquidation

Fri, 2 Dec 2016 22:15:00 UT

NEW YORK--(BUSINESS WIRE)--BlackRock Advisors, LLC announced today that the Board of Trustees of BlackRock Defined Opportunity Credit Trust (NYSE:BHL) (the “Trust) approved the adoption of a Plan of Liquidation and the termination of the Trust on or before August 31, 2017, consistent with the Trust’s investment objectives. The Trust’s investment objectives and policies are not designed to seek to return to investors the initial offering price per common share on the termination date. Under the



Dreyfus Municipal Bond Infrastructure Fund, Inc. (NYSE: DMB) Announces Dividend

Fri, 2 Dec 2016 22:09:00 UT

NEW YORK--(BUSINESS WIRE)--Dreyfus Municipal Bond Infrastructure Fund, Inc. (NYSE:DMB) today announced a distribution of $0.0530 per share of common stock, payable on January 3, 2017 to shareholders of record at the close of business on December 16, 2016. The ex-dividend date is December 14, 2016. The previous dividend announced in October was $0.0530 per share of common stock. The Fund intends to make regular monthly distributions to its common shareholders at a level rate based on its project



SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Zimmer Biomet Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

Fri, 2 Dec 2016 22:09:00 UT

LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) concerning possible violations of federal securities laws between September 7, 2016 and October 31, 2016 inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Tenet shares during the Class Period, are encouraged to contact the firm in advance of the January 31, 2016 lead plaintiff motion dea


Media Files:
http://mms.businesswire.com/media/20161202005784/en/494879/21/Lundin_Logo_Final.jpg




Jerry's ABRA Auto Body & Glass of Mankato Donates $4,900 to the Alzheimer's Association

Fri, 2 Dec 2016 22:08:00 UT

MINNEAPOLIS--(BUSINESS WIRE)--Jerry's Auto Body & Glass of Mankato Donates $4,900 to the Alzheimer's Association


Media Files:
http://mms.businesswire.com/media/20161202005781/en/1110/2/ABRA_logo.jpg




Delaware Investments® Municipal Income Funds Announce Dividends

Fri, 2 Dec 2016 21:56:00 UT

PHILADELPHIA--(BUSINESS WIRE)--Today, the following three Delaware Investments municipal income funds, all closed-end management investment companies, declare their monthly income dividends: Delaware Investments Colorado Municipal Income Fund, Inc.; Delaware Investments National Municipal Income Fund; and Delaware Investments Minnesota Municipal Income Fund II, Inc. (together, the “Funds”). The investment objective of Delaware Investments Colorado Municipal Income Fund, Inc. and Delaware Invest



Dollywood Foundation Announces Details for My People Fund

Fri, 2 Dec 2016 21:55:00 UT

PIGEON FORGE, Tenn.--(BUSINESS WIRE)--DOLLYWOOD FOUNDATION ANNOUNCES DETAILS FOR MY PEOPLE FUND



Fitch Affirms Torchmark Corporation's Ratings; Outlook Stable

Fri, 2 Dec 2016 21:53:00 UT

CHICAGO--(BUSINESS WIRE)--Fitch Ratings has affirmed Torchmark Corporation's (TMK) Issuer Default Rating (IDR) at 'A-' and the Insurer Financial Strength (IFS) ratings for TMK's insurance subsidiaries at 'A+'. The Rating Outlook is Stable. A complete list of rating actions follows at the end of this release. KEY RATING DRIVERS Fitch's ratings on TMK reflect the company's very strong and stable operating profitability, strong competitive position in its niche small-face-amount life and supplemen



New Store Information Management System Performs Well During Black Friday Week

Fri, 2 Dec 2016 21:52:00 UT

PLANO, Texas--(BUSINESS WIRE)--Rent-A-Center’s New Store Information Management System Performs Well During Strong Black Friday Week


Media Files:
http://mms.businesswire.com/media/20161202005772/en/8397/21/JPEG_RAC_Logo_9.0_CMYK.jpg




Fitch Affirms Brevard County School Board, FL's COPs 'AA-'; Outlook Stable

Fri, 2 Dec 2016 21:52:00 UT

AUSTIN, Texas--(BUSINESS WIRE)--Fitch Ratings has affirmed the 'AA-' rating on the following Brevard County School Board (the district), FL certificates of participation (COPs): --$442.2 million, COPs series 2007A, B,C; 2008A; 2013A &B; 2014; 2015B &C. In addition, Fitch has affirmed the district's Issuer Default Rating (IDR) at 'AA'. The Rating Outlook is Stable SECURITY The district's COPs are secured by lease payments made to the trustee and pursuant to a master lease purchase agreem



Citigroup Inc. Announces Offers to Purchase Five Series of Outstanding Notes

Fri, 2 Dec 2016 21:45:00 UT

NEW YORK--(BUSINESS WIRE)--Citigroup Inc. (“Citigroup”) today announced the commencement of offers to purchase for cash (i) any and all of its notes of the series set forth in the first table below, under the heading “Any and All Notes,” (the “Any and All Notes”) and (ii) certain of its notes of the series set forth in the second table below, under the heading “Maximum Tender Notes,” (the “Maximum Tender Notes”) up to an aggregate principal amount with respect to each series of Maximum Tender N


Media Files:
http://mms.businesswire.com/media/20161202005754/en/311741/21/00000CitiLogoBlue210_1.jpg




Tenet and UnitedHealthcare Renew National Relationship

Fri, 2 Dec 2016 21:45:00 UT

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) and UnitedHealthcare (NYSE: UNH) have renewed their national relationship for four years, ensuring all UnitedHealthcare commercial and Medicare Advantage plan participants have continued in-network access to Tenet’s hospitals, outpatient centers and employed physicians across the country. “We are pleased to complete this agreement ahead of schedule, allowing for continued, uninterrupted access for patients with UnitedHealthcare’s


Media Files:
http://mms.businesswire.com/media/20161202005769/en/558217/21/2755148_UHCLogo.jpg




Fitch Affirms Marion County School Board, FL's COPs at 'A'; Outlook Stable

Fri, 2 Dec 2016 21:45:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--Fitch has affirmed the following Marion County School Board (the district), FL ratings: --$93.7 million refunding COPs at 'A'. In addition, Fitch has affirmed the district's Issuer-Default Rating (IDR) at 'A+'. The Rating Outlook is Stable. SECURITY The district's COPs are payable by lease payments made to the trustee and pursuant to a master lease purchase agreement. Lease payments are payable from legally available funds of the district, subject to annual appro



Fitch Rates $1B New York City, NY GO Bonds 'AA'; Outlook Stable

Fri, 2 Dec 2016 21:44:00 UT

NEW YORK--(BUSINESS WIRE)--Fitch Ratings has assigned an 'AA' rating to the following New York City general obligation (GO) bonds: Approximately $850,000,000 fiscal 2017 series B, consisting of: --$650,000,000 tax-exempt bonds, subseries B-1; --$150,560,000 taxable bonds, subseries B-2; --$49,440,000 taxable bonds, subseries B-3; The city's Issuer Default Rating (IDR) is 'AA'. The Rating Outlook is Stable. The fiscal 2017 subseries B-1 bonds are scheduled to price via negotiation with the insti



Delaware Enhanced Global Dividend and Income Fund Announces Dividends

Fri, 2 Dec 2016 21:42:00 UT

PHILADELPHIA--(BUSINESS WIRE)--Today, Delaware Enhanced Global Dividend and Income Fund (the “Fund”), a New York Stock Exchange–listed closed-end fund trading under the symbol “DEX,” declares a monthly dividend of $0.0525 per share. The dividend is payable Dec. 30, 2016, to shareholders of record at the close of business on Dec. 16, 2016. The ex-dividend date will be Dec. 14, 2016. The Fund's primary investment objective is to seek current income, with a secondary objective of capital appreciat



Delaware Investments® Dividend and Income Fund, Inc. Announces Dividends

Fri, 2 Dec 2016 21:42:00 UT

PHILADELPHIA--(BUSINESS WIRE)--Today, Delaware Investments Dividend and Income Fund, Inc. (the “Fund”), a New York Stock Exchange–listed closed-end fund trading under the symbol “DDF,” declares a monthly dividend of $0.0400 per share. This dividend is payable Dec. 30, 2016, to shareholders of record at the close of business on Dec. 16, 2016. The ex-dividend date will be Dec. 14, 2016. The Fund is a diversified closed-end fund. The primary investment objective is to seek high current income; cap



Fitch Publishes Updated U.S. Banking Quarterly

Fri, 2 Dec 2016 21:41:00 UT

CHICAGO--(BUSINESS WIRE)--Fitch Ratings today published an updated version of its 'U.S. Banking Quarterly' with additional financial information and spreads provided for the banks covered in the report. The full report 'U.S. Banking Quarterly: Third-Quarter 2016' is available at 'www.fitchratings.com.' Additional insight into changes in bank fundamentals, as well as broader perspectives on changes in measures of credit quality, can be found in 'Fitch Fundamentals Index - U.S. (3Q16),' dated Oct



Sensient Technologies Corporation Elects Scott Morrison to its Board of Directors

Fri, 2 Dec 2016 21:38:00 UT

MILWAUKEE--(BUSINESS WIRE)--Sensient Technologies today announced the election of Scott Morrison to its Board of Directors. Mr. Morrison is Senior Vice President and Chief Financial Officer of Ball Corporation, a leading global supplier of innovative, sustainable packaging solutions for beverage, food and household products customers. Ball Corporation and its subsidiaries employ 18,700 people worldwide and reported proforma 2015 sales of $11 billion. Prior to joining Ball Corporation, Mr. Morri


Media Files:
http://mms.businesswire.com/media/20161202005758/en/92259/21/Sensient_Logo.jpg




Fitch Affirms Denver West Metro District, CO's GO Bonds at 'A-'; Outlook Stable

Fri, 2 Dec 2016 21:38:00 UT

AUSTIN, Texas--(BUSINESS WIRE)--Fitch Ratings has affirmed the 'A-' rating on the following bonds of Denver West Metropolitan District, CO: --$51.8 million in outstanding general obligation (GO) bonds. Fitch has also withdrawn the district's Issuer Default Rating (IDR) due to a lack of operating risk. The Rating Outlook is Stable. SECURITY The bonds are payable from an unlimited ad valorem tax levied against all taxable property within the district. KEY RATING DRIVERS The district's revenue bas



beIN SPORTS Announces 2016 – 2017 College Basketball Programming & Schedule

Fri, 2 Dec 2016 21:38:00 UT

MIAMI--(BUSINESS WIRE)--beIN SPORTS, the fastest growing cable network in the U.S., today announced the schedule and original programming lineup for the 2016–17 Conference USA basketball season, which begins December 3rd as Auburn tips off against UAB. The beIN SPORTS college basketball pre- and post-game studio team will be anchored by beIN SPORTS’ very own Jeremy St. Louis alongside Mike Jarvis, former St. John’s coach who brought the Red Storm to the Elite Eight in 1999 and most recently coa



Westinghouse to Resolve CB&I Purchase Agreement as Planned

Fri, 2 Dec 2016 21:34:00 UT

PITTSBURGH--(BUSINESS WIRE)--Today the Delaware Chancery Court found in favor of Westinghouse Electric Company and dismissed the filing by Chicago Bridge & Iron Company N.V. (CB&I) with respect to the post-closing reconciliation.


Media Files:
http://mms.businesswire.com/media/20161202005756/en/439438/21/westinghouse-negative_logo-blue.jpg




Fitch Affirms Harris County-Houston Sports Auth NRG Stadium Proj (TX) Bonds at 'BBB'; Outlook Stable

Fri, 2 Dec 2016 21:32:00 UT

NEW YORK--(BUSINESS WIRE)--Fitch Ratings has affirmed the 'BBB' rating of Harris County - Houston Sports Authority, TX's (the Authority) approximately $69.2 million ($62.9 million outstanding) taxable revenue refunding bonds for the NRG Stadium Project (NRG Stadium). The Rating Outlook is Stable. RATING RATIONALE The rating reflects NRG Stadium's two solid core anchor tenants, the Houston Texans (Texans) National Football League (NFL) franchise (senior notes rated 'A+'/Stable Outlook) and the H



Valvoline™ Inc. Completes Accounts Receivable Securitization Facility

Fri, 2 Dec 2016 21:30:00 UT

LEXINGTON, Ky.--(BUSINESS WIRE)--Valvoline™ Inc. (NYSE: VVV), a leading supplier of premium branded lubricants, today announced that it closed a new U.S. accounts receivable facility on November 29th, 2016. The new facility makes available up to $125 million. Certain of the Company’s lenders under its senior credit facility have committed to be purchasers under its new U.S. accounts receivable facility. The facility was established with various financial institutions. Valvoline has borrowed $75


Media Files:
http://mms.businesswire.com/media/20161202005751/en/554159/21/V_CMYK_POS_11.23.10.jpg